St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Hepatoblastoma is a type of liver cancer that is usually found in babies and children up to age 3. But it can affect children of all ages. Hepatoblastoma is the most common childhood liver cancer, but it is rare. It is diagnosed in fewer than 1 in 1 million children.
The survival rate for hepatoblastoma is more than 80% (8 in 10) if the tumor is only in the liver and can be completely removed with surgery after chemotherapy.
Survival rates for children whose tumors involve the entire liver or have spread outside the liver range from 20% (2 in 10) to 70% (7 in 10) at 3–5 years after diagnosis.
Find out more about hepatoblastoma on the Together by St. Jude™ online resource.
Surgery is used to remove all of the hepatoblastoma tumor. It is the most important part of treatment. If the entire liver is affected, your child may need a liver transplant to remove all of the tumor.
Chemotherapy uses powerful medicines to kill cancer cells or stop them from spreading. Some patients are able to have surgery upfront. But most have chemotherapy before surgery to shrink the tumor and make it easier to remove. Some patients will get chemotherapy after surgery to keep the cancer from coming back.
St. Jude Children’s Research Hospital offers clinical trials and cancer research studies for children, teens, and young adults with liver cancer. Learn more about clinical trials at St. Jude.
Study goal:
The main goal of this study is to test new experimental drugs in hopes of finding a treatment that may work against tumors that have come back or that have not responded to standard therapy in children, adolescents and young adults.
Age:
12 months to 30 years old
Study goal:
The main purpose of 3CAR is to find out if this type of immunotherapy is safe for pediatric patients with solid tumors. We also want to learn if it is effective in fighting solid tumors.
Age:
Up to 21 years old
Study goal:
The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.
Age:
12 months to 30 years
St. Jude provides the highest quality of care for patients with pediatric liver cancer:
More reasons to choose St. Jude for care include:
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
The solid tumor coordinator is dedicated to helping you seek treatment or refer a patient.
Solid Tumor Coordinator